Patents Assigned to Gilead Sciences, Inc.
  • Combination formulation of two antiviral compounds
    Patent number: 11707479
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: July 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • GLP-1R modulating compounds
    Patent number: 11702404
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
    Patent number: 11701372
    Abstract: The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott Ellis, Davin S. Rautiola, Dustin S. Siegel, Maria M. Toteva, Adelle A. Vandersteen
  • Thiadiazole IRAK4 inhibitors
    Patent number: 11702414
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • LPA receptor antagonists and uses thereof
    Patent number: 11702407
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
  • Tetracyclic compounds and uses thereof
    Patent number: 11697652
    Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: July 11, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
  • Methods of preparing carbanucleosides using amides
    Patent number: 11697666
    Abstract: The present disclosure describes methods of preparing carbanucleosides.
    Type: Grant
    Filed: April 14, 2022
    Date of Patent: July 11, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Trevor C. Johnson, Matthew Kraft, Marshall D. Young
  • Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
    Patent number: 11692038
    Abstract: Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 4, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Lara Lewis McGrath, Fabien Dépis, Changyun Hu, Leonard G. Presta, Joshua Adam Buggé
  • Capsid inhibitors for the prevention of HIV
    Patent number: 11685728
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 27, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11680064
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Antiviral pyrazolopyridinone compounds
    Patent number: 11667613
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: June 6, 2023
    Assignees: Novartis AG, Gilead Sciences, Inc.
    Inventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
  • MCL1 inhibitors
    Patent number: 11667652
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • Methods for treating SARS CoV-2 infections
    Patent number: 11660307
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
  • Thienopyrrole compounds
    Patent number: 11661431
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
  • Human immunodeficiency virus neutralizing antibodies
    Patent number: 11655285
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: May 23, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Solid forms of a Cot inhibitor compound
    Patent number: 11655237
    Abstract: Disclosed are solid forms of a Cot (cancer Osaka thyroid) inhibitor and corresponding methods of preparation thereof, wherein the Cot inhibitor has the following formula:
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 23, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Kassibla E. Dempah, Bing Shi
  • MCL-1 inhibitors
    Patent number: 11643400
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Nucleoside phosphoramidate prodrugs
    Patent number: 11642361
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Blister pack
    Patent number: D985397
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: May 9, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Robert Bridges, Joseph Cordova, Trevor Zimmermann, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot
  • Blister pack
    Patent number: D985398
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: May 9, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Robert Bridges, Joseph Cordova, Trevor Zimmermann, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot